Related references
Note: Only part of the references are listed.Fusogenic oncolytic vaccinia virus enhances systemic antitumor immune response by modulating the tumor microenvironment
Motomu Nakatake et al.
MOLECULAR THERAPY (2021)
Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade
Sharmila Nair et al.
JCI INSIGHT (2021)
Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma
Josep Malvehy et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Rational design of West Nile virus vaccine through large replacement of 3′ UTR with internal poly(A)
Ya-Nan Zhang et al.
EMBO MOLECULAR MEDICINE (2021)
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Suchit Jhunjhunwala et al.
NATURE REVIEWS CANCER (2021)
Repurposing the yellow fever vaccine for intratumoral immunotherapy
Maria Angela Aznar et al.
EMBO MOLECULAR MEDICINE (2020)
Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro
Shannon Burke et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Type 1 Interferon Responses Underlie Tumor-Selective Replication of Oncolytic Measles Virus
Sarah Aref et al.
MOLECULAR THERAPY (2020)
Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma
Nandakumar Packiriswamy et al.
LEUKEMIA (2020)
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
Yuanyuan Zhang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Oncolytic Viruses and the Immune System: The Dynamic Duo
Ana Lemos de Matos et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2020)
Neoantigen vaccine: an emerging tumor immunotherapy
Miao Peng et al.
MOLECULAR CANCER (2019)
Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade
Tala Shekarian et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
Zong Sheng Guo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines
Stephen J. Russell et al.
CANCER CELL (2018)
Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy
Jacob M. Ricca et al.
MOLECULAR THERAPY (2018)
Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy
Suman Bishnoi et al.
VIRUSES-BASEL (2018)
Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses
Olga V. Matveeva et al.
REVIEWS IN MEDICAL VIROLOGY (2018)
Treatment of Human Glioblastoma with a Live Attenuated Zika Virus Vaccine Candidate
Qi Chen et al.
MBIO (2018)
Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment
Chunmei Fu et al.
FRONTIERS IN IMMUNOLOGY (2018)
Oncolytic virus immunotherapy: future prospects for oncology
Junaid Raja et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs
Michael C. Brown et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles
Stefan Hutzler et al.
SCIENTIFIC REPORTS (2017)
Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination
Hong Jiang et al.
CANCER RESEARCH (2017)
Global Cancer Incidence and Mortality Rates and Trends-An Update
Lindsey A. Torre et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2016)
Recurrent Loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis
Tianli Xia et al.
CANCER RESEARCH (2016)
Current Challenges in Cancer Treatment
Jon Zugazagoitia et al.
CLINICAL THERAPEUTICS (2016)
Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression
Yuliya V. Katlinskaya et al.
CELL REPORTS (2016)
Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response
Carole Achard et al.
ONCOTARGET (2015)
Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers
Yuan Lin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Interferon Regulatory Factor (IRF)-1 and IRF-2 are Associated with Prognosis and Tumor Invasion in HCC
Yong Yi et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Innate Immune Defense Defines Susceptibility of Sarcoma Cells to Measles Vaccine Virus-Based Oncolysis
Susanne Berchtold et al.
JOURNAL OF VIROLOGY (2013)
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski et al.
NATURE IMMUNOLOGY (2013)
Resistance to Oncolytic Myxoma Virus Therapy in Nf1-/-/Trp53-/- Syngeneic Mouse Glioma Models Is Independent of Anti-Viral Type-I Interferon
Franz J. Zemp et al.
PLOS ONE (2013)
Oncolytic virotherapy
Stephen J. Russell et al.
NATURE BIOTECHNOLOGY (2012)
Type I Interferon-Sensitive Recombinant Newcastle Disease Virus for Oncolytic Virotherapy
Subbiah Elankumaran et al.
JOURNAL OF VIROLOGY (2010)
Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis
Vanessa Fonseca Tumilasci et al.
JOURNAL OF VIROLOGY (2008)
The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: Implication for the defective interferon response in cancer cells
Josh A. Noser et al.
MOLECULAR THERAPY (2007)
Mechanisms of type-I- and type-II-interferon-mediated signalling
LC Platanias
NATURE REVIEWS IMMUNOLOGY (2005)
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
DF Stojdl et al.
CANCER CELL (2003)
Intergeneric poliovirus recombinants for the treatment of malignant glioma
M Gromeier et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
